In a 76‑year‑old female on rehabilitation with major depressive disorder, generalized anxiety disorder, and seizure disorder treated with lamotrigine (200 mg twice daily), currently receiving vortioxetine (20 mg daily), buspirone (22.5 mg twice daily), and olanzapine (Zyprexa) (2.5 mg daily) after discontinuation of lorazepam (Ativan), how should her mood and anxiety be managed?

Management of Mood and Anxiety in a 76-Year-Old with Treatment-Resistant Depression

Optimize the current vortioxetine dose to 20 mg daily and maintain buspirone at current dosing, while avoiding reinitiation of benzodiazepines given her age and fall risk. The medical team's decision to discontinue lorazepam was appropriate and should be upheld.

Rationale for Current Medication Optimization

Vortioxetine Dose Escalation

Your patient is currently on vortioxetine 20 mg daily, which is already at the maximum FDA-approved dose. Vortioxetine demonstrates superior efficacy at 20 mg/day in patients with MDD and high anxiety symptoms 1. In the pooled analysis of patients with baseline Hamilton Anxiety Rating Scale scores ≥20, vortioxetine 20 mg showed significant improvements from week 4 onwards with a clear dose-response relationship 1.

• Vortioxetine 20 mg is particularly effective in elderly patients (≥55 years), showing mean MADRS improvement of -4.65 points versus placebo with odds ratios for response of 2.5 and remission of 2.7 2
• Long-term data (52 weeks) confirms sustained efficacy and tolerability at 15-20 mg doses in elderly populations 3
• The medication addresses both depression and anxiety symptoms simultaneously, which is critical for this patient's presentation

Buspirone Continuation

Continue buspirone 22.5 mg BID as currently prescribed. Buspirone has demonstrated efficacy specifically in elderly anxious patients at mean doses of 18 mg/day 4. The current dose of 45 mg/day total is within the therapeutic range (maximum 60 mg/day per FDA labeling 5) and below the maximum recommended dose.

• Buspirone requires 2-4 weeks to become fully effective 6
• It carries minimal risk of falls, cognitive impairment, or dependence compared to benzodiazepines
• Well-tolerated in elderly patients receiving multiple medications for chronic conditions 4

Olanzapine Augmentation Strategy

The addition of olanzapine 2.5 mg daily is evidence-based for treatment-resistant depression with anxiety. Olanzapine has demonstrated efficacy in bipolar disorder patients with comorbid anxiety disorders 7 and is recommended for augmentation in difficult-to-treat MDD with anxiety symptoms 8.

However, monitor closely for metabolic effects, sedation, and orthostatic hypotension given her age. The FDA label specifically warns about increased mortality risk in elderly patients with dementia-related psychosis 9, though this patient does not have dementia. Key monitoring includes:

• Weight and metabolic parameters (glucose, lipids) - olanzapine causes significant weight gain, especially problematic in elderly
• Blood pressure (orthostatic measurements)
• Sedation level and fall risk assessment
• Cognitive status

Why Benzodiazepines Should Remain Discontinued

The medical team's decision to discontinue lorazepam was clinically appropriate and should be maintained. While guidelines do support low-dose benzodiazepines for anxiety in specific contexts 10, the risks in this 76-year-old outweigh benefits:

Evidence Against Benzodiazepine Use in This Patient:

1. High fall risk: Benzodiazepines are strongly associated with falls in elderly patients 6
2. Cognitive impairment: Regular use leads to tolerance, addiction, depression, and cognitive decline 6
3. Anticholinergic burden: Adding to her existing medication burden increases delirium risk 11
4. Paradoxical agitation: Occurs in ~10% of elderly patients on benzodiazepines 6
5. Not first-line for chronic anxiety: Guidelines reserve benzodiazepines for acute crisis situations or alcohol/benzodiazepine withdrawal 12

If Acute Anxiety Crisis Occurs:

Only in severe, acute situations where the patient poses risk to herself, consider lorazepam 0.25-0.5 mg PRN (reduced elderly dose) 10. Maximum 2 mg in 24 hours for elderly patients 10. This should be truly PRN for crisis intervention, not scheduled dosing.

Specific Management Algorithm

Immediate Actions (Week 1-2):

1. Confirm vortioxetine 20 mg daily is being taken consistently
2. Continue buspirone 22.5 mg BID
3. Continue olanzapine 2.5 mg daily with close monitoring
4. Continue lamotrigine 200 mg BID for seizure control (do not adjust)
5. Assess for reversible causes of anxiety: pain, constipation, urinary retention, medication side effects 10

Week 2-4 Assessment:

• If anxiety remains severe despite optimization: Consider increasing olanzapine to 5 mg daily (still within safe elderly range 6)
• If excessive sedation occurs: Reduce olanzapine to 2.5 mg every other day or discontinue
• If metabolic concerns emerge: Consider switching olanzapine to quetiapine 25 mg daily (less metabolic risk, still effective for anxiety 6)

Week 4-8 Assessment:

• If partial response: Continue current regimen (vortioxetine requires 4-8 weeks for full effect 6)
• If no response: Consider psychiatric consultation for alternative augmentation strategies (aripiprazole, brexpiprazole) 8

Critical Pitfalls to Avoid

1. Do not restart scheduled benzodiazepines - the nursing request reflects discomfort with behavioral management, not medical necessity
2. Do not use anticholinergic medications (diphenhydramine, hydroxyzine) - high delirium risk in elderly 11
3. Do not abruptly discontinue any current medications - particularly lamotrigine (seizure risk) or vortioxetine (withdrawal symptoms)
4. Do not add multiple new medications simultaneously - impossible to determine what helps or causes side effects
5. Monitor for serotonin syndrome - vortioxetine plus buspirone carries theoretical risk, though rare

Non-Pharmacologic Interventions

While optimizing medications:

• Structured daily routine with regular sleep-wake times
• Physical activity as tolerated (evidence for depression/anxiety benefit 6)
• Cognitive-behavioral approaches if available through rehabilitation psychology 13
• Address environmental triggers: ensure adequate lighting, orientation cues, minimize overstimulation 10

The current medication regimen is evidence-based and appropriate. The key is allowing adequate time (4-8 weeks) for vortioxetine and buspirone to reach full efficacy 6, 4 while maintaining the olanzapine augmentation strategy and avoiding the temptation to restart benzodiazepines despite nursing pressure.